EA200701130A1 - Электропорация микобактерии и сверхэкспрессия антигенов микобактерий - Google Patents

Электропорация микобактерии и сверхэкспрессия антигенов микобактерий

Info

Publication number
EA200701130A1
EA200701130A1 EA200701130A EA200701130A EA200701130A1 EA 200701130 A1 EA200701130 A1 EA 200701130A1 EA 200701130 A EA200701130 A EA 200701130A EA 200701130 A EA200701130 A EA 200701130A EA 200701130 A1 EA200701130 A1 EA 200701130A1
Authority
EA
Eurasian Patent Office
Prior art keywords
strains
mycobacteria
superexpression
electroporation
antigens
Prior art date
Application number
EA200701130A
Other languages
English (en)
Other versions
EA012182B1 (ru
Inventor
Ронггай Сунь
Дэвид Майкл Хоун
Джералд С. Сэдофф
Original Assignee
ЭЙРАС ГЛОУБАЛ ТиБи ВЭКСИН ФАУНДЕЙШН
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЭЙРАС ГЛОУБАЛ ТиБи ВЭКСИН ФАУНДЕЙШН filed Critical ЭЙРАС ГЛОУБАЛ ТиБи ВЭКСИН ФАУНДЕЙШН
Publication of EA200701130A1 publication Critical patent/EA200701130A1/ru
Publication of EA012182B1 publication Critical patent/EA012182B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к рекомбинантным штаммам Mycobacterium, обладающим улучшенными вакцинными свойствами, позволяющими использовать эти штаммы в качестве вакцин. Штаммы для получения рекомбинантных Mycobacterium выбирают из родительских штаммов, которые были идентифицированы как штаммы, обладающие высокой иммуногенностью. Полученные штаммы Mycobacterium не обладают резистентностью к антибиотикам, и их гены не подвергаются горизонтальному переносу в грам-отрицательные бактерии.
EA200701130A 2004-12-01 2005-11-29 Электропорация микобактерии и сверхэкспрессия антигенов микобактерий EA012182B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63197704P 2004-12-01 2004-12-01
PCT/US2005/042976 WO2006060332A2 (en) 2004-12-01 2005-11-29 Electroporation of mycobacterium and overexpression of antigens in mycobacteria

Publications (2)

Publication Number Publication Date
EA200701130A1 true EA200701130A1 (ru) 2007-12-28
EA012182B1 EA012182B1 (ru) 2009-08-28

Family

ID=36565595

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701130A EA012182B1 (ru) 2004-12-01 2005-11-29 Электропорация микобактерии и сверхэкспрессия антигенов микобактерий

Country Status (16)

Country Link
US (1) US7625572B2 (ru)
EP (1) EP1817061B1 (ru)
JP (1) JP5461776B2 (ru)
KR (1) KR101382215B1 (ru)
CN (1) CN101076356B (ru)
AP (1) AP2869A (ru)
AT (1) ATE517637T1 (ru)
AU (1) AU2005312062B2 (ru)
BR (1) BRPI0518080A (ru)
CA (1) CA2587507C (ru)
DK (1) DK1817061T3 (ru)
EA (1) EA012182B1 (ru)
ES (1) ES2370885T3 (ru)
MX (1) MX2007006552A (ru)
WO (1) WO2006060332A2 (ru)
ZA (1) ZA200704764B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829104B2 (en) * 2004-12-01 2010-11-09 Aeras Global Tb Vaccine Foundation Electroporation of Mycobacterium and overexpression of antigens in mycobacteria
CA2589204C (en) 2004-12-01 2013-10-29 Aeras Global Tb Vaccine Foundation Recombinant bcg strains with enhanced ability to escape the endosome
US8682619B2 (en) * 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8852916B2 (en) * 2010-01-22 2014-10-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with microorganisms
US8734823B2 (en) * 2005-12-14 2014-05-27 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US20110172826A1 (en) * 2005-12-14 2011-07-14 Amodei Dario G Device including altered microorganisms, and methods and systems of use
US8278094B2 (en) 2005-12-14 2012-10-02 The Invention Science Fund I, Llc Bone semi-permeable device
US20090304750A1 (en) * 2005-12-15 2009-12-10 David Hone Novel prime-boost combinations of attenuated mycobacterium
WO2009045575A2 (en) * 2007-06-14 2009-04-09 The Regents Of The University Of California Unmarked recombinant intracellular pathogen immunogenic compositions expressing high levels of recombinant proteins
EP2834356A4 (en) * 2012-04-02 2015-09-02 Univ Arizona RECOMBINANT BACTERIUM FOR INDUCING A CELLULAR IMMUNE RESPONSE
WO2013158061A1 (en) 2012-04-16 2013-10-24 Aeras Global Tb Vaccine Foundation Recombinant mycobacterium encoding a heparin-binding hemagglutinin (hbha) fusion protein and uses thereof
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736367A (en) * 1992-03-31 1998-04-07 Medimmune, Inc. Vectors and prokaryotes which autocatalytically delete antibiotic resistance
US5783386A (en) * 1994-02-24 1998-07-21 Agresearch, New Zealand Pastoral Agriculture Research Institute Ltd. Mycobacteria virulence factors and a novel method for their identification
DE69532524D1 (de) * 1994-07-29 2004-03-11 Ajinomoto Kk Sekretorischer rekombinanter bcg impfstoff gegen aids
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US6004815A (en) * 1998-08-13 1999-12-21 The Regents Of The University Of California Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells
US6423545B1 (en) * 1999-07-08 2002-07-23 Albert Einstein College Of Medicine Of Yeshiva University Unmarked deletion mutants of mycobacteria and methods of using same
US6562348B2 (en) * 1999-07-08 2003-05-13 Albert Einstein College Of Medicine Of Yeshiva University Recombinant M. tuberculosis auxotrophic for leucine and vaccines using same
CN1342771A (zh) * 2001-09-17 2002-04-03 复旦大学 结核分枝杆菌Ag85B抗原的表达纯化和作为疫苗组份的应用
WO2006072787A1 (en) * 2005-01-05 2006-07-13 Isis Innovation Limited Compositions for immunizing against mycobacterium

Also Published As

Publication number Publication date
WO2006060332A2 (en) 2006-06-08
KR101382215B1 (ko) 2014-04-08
AP2007004021A0 (en) 2007-06-30
CA2587507C (en) 2013-11-19
JP2008521435A (ja) 2008-06-26
ATE517637T1 (de) 2011-08-15
EP1817061A4 (en) 2009-07-08
KR20070111452A (ko) 2007-11-21
EA012182B1 (ru) 2009-08-28
CN101076356B (zh) 2013-04-03
CN101076356A (zh) 2007-11-21
MX2007006552A (es) 2007-08-20
US20060121054A1 (en) 2006-06-08
EP1817061B1 (en) 2011-07-27
US7625572B2 (en) 2009-12-01
JP5461776B2 (ja) 2014-04-02
AU2005312062B2 (en) 2011-11-17
WO2006060332A3 (en) 2006-08-03
AU2005312062A1 (en) 2006-06-08
CA2587507A1 (en) 2006-06-08
ZA200704764B (en) 2008-09-25
DK1817061T3 (da) 2011-11-14
AP2869A (en) 2014-03-31
EP1817061A2 (en) 2007-08-15
ES2370885T3 (es) 2011-12-23
BRPI0518080A (pt) 2008-10-28

Similar Documents

Publication Publication Date Title
EA200701130A1 (ru) Электропорация микобактерии и сверхэкспрессия антигенов микобактерий
DK2566507T3 (da) Biokonjugatvacciner med kapselformige grampositive bakterier
EP4043031A3 (en) Zika viral antigen constructs
NZ607996A (en) Substituted nucleotide analogs
CY1114271T1 (el) Αντισωματα εξουδετερωσης, ανθρωπινου κυτταρομεγαλοϊου και χρηση αυτων
AU2017297757A1 (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
EA035991B9 (ru) Новый полисахарид и его применения
MX2016009072A (es) Fusion de antigenos micobacterianos heterooligomericos.
EP2562183A8 (en) Novel immunogenic epitopes for immunotherapy
SI1951296T2 (sl) Iz celic izpeljana virusna cepiva z nizko stopnjo preostale celiäśne dna z obdelavo z betapropiolaktonom
PH12014502855A1 (en) Attenuated streptococcus suis vaccines and methods of making and use thereof
TNSN07387A1 (en) C.perfringens alpha toxoid vaccine
DK2280721T3 (da) Indoleamin-2, 3-dioxygenasebaseret immunterapi
EA201491171A1 (ru) Вещества, содержащие улучшенные генетические конструкции il-12, вакцины, иммунотерапевтические составы и способы их применения
MX370744B (es) Una vacuna antituberculosis tb para evitar la reactivación.
WO2016073595A8 (en) T cells and dendritic cells for polyomavirus therapy
MX2018010483A (es) Inmunogenos para vacunacion contra vih.
MX2010002867A (es) Cepas de micoplasma atenuadas vivas.
EP2574170A4 (en) IMMUNOSTIMULATORY AND VACCINE COMPOSITIONS
WO2009135199A3 (en) Vaccine compositions and methods
WO2015148687A3 (en) Immunological compositions containing attenuated histophilus somni
GB201017519D0 (en) Vaccines
ZA202107428B (en) Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof
WO2016038625A3 (en) Superior human papilloma virus antigens with superior immunological properties and vaccine containing it
WO2016075546A3 (en) Antibodies that neutralize ebola virus and uses thereof